Version 2.80

Description

Bruton's tyrosine kinase (BTK) plays a crucial role in oncogenic signaling that is critical for proliferation and survival of leukemic cells in many B cell malignancies. BTK was initially shown to be defective in the primary immunodeficiency X-linked agammaglobulinemia (XLA) and B cell development and the function of mature B cells. The orally administered irreversible BTK inhibitor ibrutinib is associated with high response rates in patients with relapsed/refractory chronic lymphocytic leukemia (CLL). PMID: 29455639 Source: NCBI PubMed

Basic Part Properties

Part Name
BTK gene targeted mutation analysis
Part Display Name
BTK gene targeted mutation analysis
Part Type
Component (Describes the core component or analyte measured)
Created On
2016-09-13
Construct for LOINC Short Name
BTK gene targeted mutation analysis

LOINC Terminology Service (API) using HL7® FHIR® Get Info

CodeSystem lookup
https://fhir.loinc.org/CodeSystem/$lookup?system=http://loinc.org&code=LP227842-4